BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Monday, March 18, 2024
Home
»
Newsletters
» BioWorld
BioWorld
April 7, 2008
View Archived Issues
Money Raised By Month
Read More
Stock Winners and Losers For The Week
Read More
Public Financing Of Biotechnology: March 2008
Read More
Other Financings Of Public Biotechnology Companies: March 2008
Read More
Venture Capital And Other Investments In Private Biotechnology Companies: March 2008
Read More
Vytorin Miss Could Open Wider Window for Others
Genzyme Corp.'s pricey January deal for Isis Pharmaceuticals Inc.'s cholesterol-lowering drug mipomersen - considered too expensive at the time by some - is looking more reasonable by the minute. (BioWorld Financial Watch)
Read More
Milestone Payments From Corporate Partners: March 2008
Read More
Money Raised in 2008
Read More
Stock Indexes
Read More
BioWorld Stock Report For Public Biotechnology Companies
Read More